

## CLAIMS

1-46. Cancelled

47. (currently amended) A method for accelerating angiogenesis in a patient comprising: topically administering to the patient, at a site where angiogenesis acceleration is desired, ~~of~~ a fibrin matrix made by the process of forming ~~a~~ the fibrin matrix from a composition comprising fibrinogen and a pharmaceutically acceptable carrier, wherein the fibrinogen has a high molecular weight (HMW) content of at least 80 % (w/w) of the total fibrinogen amount.

48. (previously presented) The method of claim 47, where wherein the high molecular weight fibrinogen content is a mixture enriched in the Fib420 form of fibrinogen.

49. (currently amended) The method of claim 47 where the fibrin matrix is applied to burnt tissue of a patient.

50. (currently amended) The method of claim 47 where the fibrin matrix is applied to wounded tissue of ~~a~~ the patient.

51. (currently amended) The method of claim 47 where the fibrin matrix is applied to an internal organ of ~~a~~ the patient during a surgical procedure.

52. (previously presented) The method of claim 47, wherein the composition further contains one of more of factor XIIIa, CaCl<sub>2</sub> or an enzyme capable of forming fibrin from fibrinogen.

53. (previously presented) The method of claim 52, where the enzyme is thrombin.

54. (currently amended) A method for decelerating angiogenesis in a patient comprising: topically administering to the patient, at a site where angiogenesis deceleration is desired, ~~intravenous injection or infusion of~~ a fibrin matrix made by the process of forming a fibrin matrix from a composition comprising fibrinogen and a pharmaceutically acceptable carrier, wherein the fibrinogen has a low molecular weight content (LMW) of at least 40 % (w/w) of the total fibrinogen amount, ~~forming a fibrin matrix from said composition.~~

55. (previously presented) The method of claim 54, where wherein the low molecular weight fibrinogen content is a mixture enriched in the gamma form of fibrinogen.

56. (previously presented) The method of claim 54, wherein the composition further contains one of more of factor XIIIa, CaCl<sub>2</sub> or an enzyme capable of forming fibrin from fibrinogen.

57. (previously presented) The method of claim 56, where the enzyme is thrombin.

58. (canceled)

59. (currently amended) The method of claim 54 where the composition is topically administered to an internal organ of a patient during the course of a surgical procedure.

60-61. (canceled)

62. (currently amended) The method of claim ~~58~~54 where the composition is applied to a wound of a patient to lessen scar formation or adhesions of the wound.

63-68. (canceled)